Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey R Oxnard

Showing results (171-180 of 199) with videos related to

Pageof 20
Sort By:
The Journal of Molecular Diagnostics : JMD|January 4, 2026
Phenotypic POLE variant classification identifies patients who may have favorable prognosis and benefit from immunotherapyRachel B Keller-Evans, Zoe Fleischmann, Smruthy Sivakumar, et al.
Science Translational Medicine|July 8, 2011
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modelingJuliann Chmielecki, Jasmine Foo, Geoffrey R Oxnard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2021
Intracranial Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 TrialVivek Subbiah, Justin F Gainor, Geoffrey R Oxnard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2020
Phase IB Study of Osimertinib in Combination with Navitoclax in <i>EGFR</i>-mutant NSCLC Following Resistance to Initial <i>EGFR</i> Therapy (ETCTN 9903)Erin M Bertino, Ryan D Gentzler, Sarah Clifford, et al.
Cancer|August 11, 2021
Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancerAndrea Necchi, Vito Cucchiara, Petros Grivas, et al.
Journal for Immunotherapy of Cancer|February 6, 2025
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer typesDavid R Gandara, Neeraj Agarwal, Shilpa Gupta, et al.
Histopathology|February 29, 2024
Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable resultsDouglas A Mata, Jessica K Lee, Vignesh Shanmugam, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2019
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung CancerLeora Horn, Jennifer G Whisenant, Heather Wakelee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2023
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURAJhanelle E Gray, Myung-Ju Ahn, Geoffrey R Oxnard, et al.
Archives of Pathology & Laboratory Medicine|June 30, 2022
Method of Tissue Acquisition Affects Success of Comprehensive Genomic Profiling in Lung CancerDouglas A Mata, Lukas Harries, Erik A Williams, et al.
Pageof 20

Showing results (171-180 of 199) with videos related to

Sort By:
Pageof 20
The Journal of Molecular Diagnostics : JMD|January 4, 2026
Phenotypic POLE variant classification identifies patients who may have favorable prognosis and benefit from immunotherapyRachel B Keller-Evans, Zoe Fleischmann, Smruthy Sivakumar, et al.
Science Translational Medicine|July 8, 2011
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modelingJuliann Chmielecki, Jasmine Foo, Geoffrey R Oxnard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2021
Intracranial Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 TrialVivek Subbiah, Justin F Gainor, Geoffrey R Oxnard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2020
Phase IB Study of Osimertinib in Combination with Navitoclax in <i>EGFR</i>-mutant NSCLC Following Resistance to Initial <i>EGFR</i> Therapy (ETCTN 9903)Erin M Bertino, Ryan D Gentzler, Sarah Clifford, et al.
Cancer|August 11, 2021
Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancerAndrea Necchi, Vito Cucchiara, Petros Grivas, et al.
Journal for Immunotherapy of Cancer|February 6, 2025
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer typesDavid R Gandara, Neeraj Agarwal, Shilpa Gupta, et al.
Histopathology|February 29, 2024
Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable resultsDouglas A Mata, Jessica K Lee, Vignesh Shanmugam, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2019
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung CancerLeora Horn, Jennifer G Whisenant, Heather Wakelee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2023
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURAJhanelle E Gray, Myung-Ju Ahn, Geoffrey R Oxnard, et al.
Archives of Pathology & Laboratory Medicine|June 30, 2022
Method of Tissue Acquisition Affects Success of Comprehensive Genomic Profiling in Lung CancerDouglas A Mata, Lukas Harries, Erik A Williams, et al.
Pageof 20